Currently, there are 488.92M common shares owned by the public and among those 301.06M shares have been available to trade.
The company’s stock has a 5-day price change of -4.82% and 8.50% over the past three months. RKLB shares are trading -21.52% year to date (YTD), with the 12-month market performance down to -23.59% lower. It has a 12-month low price of $3.47 and touched a high of $8.05 over the same period. RKLB has an average intraday trading volume of 7.37 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.05%, 6.50%, and -3.75% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Rocket Lab USA Inc (NASDAQ: RKLB) shares accounts for 30.14% of the company’s 488.92M shares outstanding.
It has a market capitalization of $2.14B and a beta (3y monthly) value of 1.23. The earnings-per-share (ttm) stands at -$0.37. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.87% over the week and 4.32% over the month.
Earnings per share for the fiscal year are expected to decrease by -31.72%, and 41.51% over the next financial year.
Looking at the support for the RKLB, a number of firms have released research notes about the stock. Goldman stated their Neutral rating for the stock in a research note on June 11, 2024, with the firm’s price target at $4.50. Citigroup coverage for the Rocket Lab USA Inc (RKLB) stock in a research note released on February 12, 2024 offered a Buy rating with a price target of $6. KeyBanc Capital Markets was of a view on January 17, 2024 that the stock is Overweight, while Cantor Fitzgerald gave the stock Overweight rating on October 26, 2023, issuing a price target of $6. Citigroup on their part issued Neutral rating on April 18, 2023.
